Cargando…

Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis

Background and Aim: Alpha-fetoprotein (AFP), a lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), is a protein that is induced by vitamin K deficiency or antagonist-II (PIVKA-II) that has been clinically used as a serum biomarker for early detection and diagnosis of hepatocellular carcinom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Siyu, Sun, Liyang, Yao, Lanqing, Zhu, Hong, Diao, Yongkang, Wang, Mingda, Xing, Hao, Lau, Wan Yee, Guan, Mingcheng, Pawlik, Timothy M., Shen, Feng, Xu, Min, Tong, Xiangmin, Yang, Tian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456633/ https://www.ncbi.nlm.nih.gov/pubmed/36079006 http://dx.doi.org/10.3390/jcm11175075

Ejemplares similares

Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma
por: Park, Sang Joon, et al.
Publicado: (2017)

The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma
por: Qi, Famei, et al.
Publicado: (2019)

Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients
por: Ren, Tianying, et al.
Publicado: (2023)

The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients
por: Xu, Fei, et al.
Publicado: (2021)

The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma
por: Tran, Vinh Thanh, et al.
Publicado: (2023)

PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma
por: Feng, Honglei, et al.
Publicado: (2021)

The value of PIVKA-Ⅱ versus AFP for the diagnosis and detection of postoperative changes in hepatocellular carcinoma
por: Lee, Qiuyan, et al.
Publicado: (2021)

Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis
por: Chan, Henry L Y, et al.
Publicado: (2022)

Clinical value of serum AFP and PIVKA‐II for diagnosis, treatment and prognosis of hepatocellular carcinoma
por: Tian, Shan, et al.
Publicado: (2022)

Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients
por: Hadi, Hana, et al.
Publicado: (2022)

PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients
por: Suttichaimongkol, Tanita, et al.
Publicado: (2023)

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
por: Kim, Do Young, et al.
Publicado: (2023)

Effect of PIVKA‐II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery
por: Cai, Yunshi, et al.
Publicado: (2023)

Clinical Significance of AFP and PIVKA-II Responses for Monitoring Treatment Outcomes and Predicting Prognosis in Patients with Hepatocellular Carcinoma
por: Park, Hana, et al.
Publicado: (2013)

Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation
por: Si, Yuan-Quan, et al.
Publicado: (2020)

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
por: Sun, Xuqi, et al.
Publicado: (2021)

Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population
por: Zheng, Kepu, et al.
Publicado: (2023)

AFP
Publicado: (2009)

Status of AFP
por: Erland, Paula Agnieszka
Publicado: (2019)

The AFP Project
por: Staszewski, R.
Publicado: (2011)

Alpha-Fetoprotein (AFP) and AFP-L3 Is Most Useful in Detection of Recurrence of Hepatocellular Carcinoma in Patients after Tumor Ablation and with Low AFP Level
por: Force, Madison, et al.
Publicado: (2022)

TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma
por: Mao, Liping, et al.
Publicado: (2017)

Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis
por: Wang, Xueying, et al.
Publicado: (2020)

DCS and TDAQ for AFP
por: Banas, Elzbieta, et al.
Publicado: (2017)

AFP Project in ATLAS
por: Tasevsky, M
Publicado: (2017)

First AFP results
por: Staszewski, Rafal
Publicado: (2017)

Overview of AFP performance
por: Liu, Jesse Kar Kee
Publicado: (2021)

The ATLAS AFP Spectrometer
por: Newman, Paul Richard
Publicado: (2021)

Overview of AFP Detector
por: Auriol, Adrien
Publicado: (2023)

Simple Clinical Metrics Enhance AFP to Effectively Identify Cirrhotic Patients With Complicating Hepatocellular Carcinoma at Various AFP Levels
por: Zhang, Xi, et al.
Publicado: (2020)

Identification of Plasma hsa_circ_0005397 and Combined With Serum AFP, AFP-L3 as Potential Biomarkers for Hepatocellular Carcinoma
por: Liu, Ruoyu, et al.
Publicado: (2021)

Analysis of serum alpha-fetoprotein (AFP) and AFP-L3 levels by protein microarray
por: Wu, Min, et al.
Publicado: (2018)

Real impact of tumor marker AFP and PIVKA-II in detecting very small hepatocellular carcinoma (≤ 2 cm, Barcelona stage 0) - assessment with large number of cases
por: Tarao, Kazuo, et al.
Publicado: (2020)

Status of the AFP Project in ATLAS
por: Tasevsky, Marek
Publicado: (2017)

ATLAS AFP: Status and Prospects
por: Newman, Paul
Publicado: (2018)

The AFP detector control system
por: Oleiro Seabra, Luis Filipe, et al.
Publicado: (2017)

The AFP and CT-PPS projects
por: Royon, C., et al.
Publicado: (2015)

Physics goals and status of AFP
por: Trzebinski, Maciej
Publicado: (2015)

Backgrounds in AFP Detector Estimation
por: Huang, Yicong
Publicado: (2016)

The tracking system of the AFP detector.
por: Dyndal, M
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kg444kla9t64fu5pjh4ti7djgp